← All companies
PFE
PFIZER INC · Health Care
8 quarters · 53 figures · latest Q3 FY2026 filed 2026-11-03 →
Compared
6 of 8 · select any line below to add or remove it ·
TOTAL REVENUES
$16.58bn−0.4% Y/YQ3 FY2026
Reported Net Income
$3.24bn−8.4% Y/YQ3 FY2026
Reported Diluted EPS
$0.56−9.7% Y/YQ3 FY2026
Acquired in-process research and development expenses
$669m−51.9% Y/YQ3 FY2026
Alliance revenues
$2.85bn+24.1% Y/YQ3 FY2026
Amortization of intangible assets
$1.13bn−7.8% Y/YQ3 FY2026
Reported figures
Click any line for its full history. Each figure links to the filing it was read from.
Income statement
25 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Acquired in-process research and development expensesacquired_iprd_expense | $212m | $137m | $16m | $669m | −51.9% | +4081.3% | |
| Alliance revenuesalliance_revenue | $2.58bn | $2.34bn | $2.7bn | $2.85bn | +24.1% | +5.7% | |
| Amortization of intangible assetsamortization_of_intangibles | $1.23bn | $1.18bn | $1.19bn | $1.13bn | −7.8% | −4.8% | |
| Cost of salescost_of_sales | $5.27bn | $3.55bn | $4.09bn | $4.03bn | −3.5% | −1.6% | |
| Adjusted Cost of Salescost_of_sales_non_gaap | $5.07bn | $3.41bn | $3.66bn | $3.84bn | −3.4% | +5.1% | |
| Reported Diluted EPSeps_diluted | −$0.29 | $0.47 | −$0.04 | $0.56 | −9.7% | +1500.0% | |
| Adjusted Diluted EPSeps_diluted_non_gaap | $0.66 | $0.75 | $0.77 | $0.87 | +0.0% | +13.0% | |
| Provision/(benefit) for taxes on incomeincome_tax_provision | −$2m | $461m | −$407m | $134m | +162.0% | +132.9% | |
| Reported Net Incomenet_income | −$1.65bn | $2.69bn | −$248m | $3.24bn | −8.4% | +1407.3% | |
| Adjusted Incomenet_income_non_gaap | $3.79bn | $4.29bn | $4.44bn | $4.99bn | +0.7% | +12.3% | |
| Income from continuing operations before provision/(benefit) for taxes on incomepretax_income | −$1.64bn | $3.17bn | −$653m | $3.39bn | +1.5% | +618.4% | |
| Product revenuesproduct_revenue | $14.5bn | $11.72bn | $11.86bn | $13.26bn | −4.8% | +11.7% | |
| Research and development expensesrd_expense | $3.21bn | $2.49bn | $2.81bn | $3.02bn | +18.5% | +7.4% | |
| Adjusted R&D Expensesrd_expense_non_gaap | $3.12bn | $2.43bn | $2.73bn | $2.94bn | +18.3% | +7.8% | |
| Restructuring charges and certain acquisition-related costsrestructuring_and_acquisition_costs | $604m | $100m | $457m | $791m | +176.6% | +73.1% | |
| Royalty revenuesroyalty_revenue | $480m | $396m | $474m | $477m | +9.4% | +0.6% | |
| Selling, informational and administrative expensessga_expense | $4.16bn | $2.96bn | $3.41bn | $3.28bn | +2.9% | −3.9% | |
| Adjusted SI&A Expensessga_expense_non_gaap | $4.08bn | $2.92bn | $3.34bn | $3.22bn | +2.0% | −3.7% | |
| TOTAL REVENUEStotal_revenue | $17.56bn | $14.45bn | $15.03bn | $16.58bn | −0.4% | +10.3% | |
| Diluted weighted-average shares (millions)diluted_shares | — | 5,731 | 5,699 | 5,751 | +0.6% | +0.9% | |
| Other (income)/deductions––netother_income_deductions_net | — | $861m | $3.72bn | $288m | −44.3% | −92.2% | |
| Adjusted Other (Income)/Deductions—netother_income_deductions_net_non_gaap | — | $388m | $108m | $102m | −60.3% | −5.6% | |
| Income/(loss) from continuing operationsincome_from_continuing_operations | −$1.64bn | — | — | — | −499.0% | — | |
| Other (Income)/Deductions—netother_deductions_net | $4.51bn | — | — | — | +91.4% | — | |
| Adjusted Other (Income)/Deductions—netother_deductions_net_non_gaap | $139m | — | — | — | −40.6% | — |
Segments
12 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Oncologyoncology_revenue | $4.44bn | $3.83bn | $4.17bn | $4.33bn | +9.9% | +3.9% | |
| Primary Careprimary_care_revenue | $7.94bn | $5.54bn | $5.5bn | $6.97bn | −8.8% | +26.7% | |
| Global Biopharmaceuticals Business (Biopharma)segment_biopharma_revenue | $17.14bn | $14.16bn | $14.66bn | $16.28bn | −0.2% | +11.1% | |
| Pfizer CentreOnesegment_pfizer_centreone_revenue | $409m | $289m | $373m | $300m | −12.8% | −19.6% | |
| Specialty Carespecialty_care_revenue | $4.77bn | $2.94bn | $3.35bn | $3.35bn | +7.0% | −0.1% | |
| GLOBAL HOSPITAL AND BIOSIMILARS DIVISIONglobal_hospital_biosimilars_division_revenue | — | $1.24bn | $1.16bn | $1.17bn | +9.0% | +0.9% | |
| Hospital and Biosimilarshospital_and_biosimilars_revenue | — | $1.85bn | $1.64bn | $1.64bn | +2.2% | −0.3% | |
| PFIZER INTERNATIONAL COMMERCIAL DIVISIONinternational_commercial_division_revenue | — | $5.23bn | $5.54bn | $5.43bn | +1.0% | −2.0% | |
| Total International revenuesinternational_revenue | — | $5.72bn | $6.18bn | $5.98bn | +0.3% | −3.2% | |
| PFIZER U.S. COMMERCIAL DIVISIONus_commercial_division_revenue | — | $7.69bn | $7.96bn | $9.68bn | −1.8% | +21.6% | |
| United States total revenuesus_revenue | — | $8.73bn | $8.86bn | $10.6bn | −0.8% | +19.7% | |
| Pfizer Ignitesegment_pfizer_ignite_revenue | $4m | — | — | — | −84.6% | — |
Operating
12 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Comirnatycomirnaty_revenue | $2.27bn | $232m | $261m | $808m | −29.8% | +209.6% | |
| Eliquiseliquis_revenue | $2.02bn | $2.17bn | $2.43bn | $2.52bn | +25.2% | +4.0% | |
| Ibranceibrance_revenue | $1.04bn | $1.01bn | $1.06bn | $1.08bn | +2.4% | +2.3% | |
| Nurtec ODT/Vyduranurtec_revenue | $405m | $353m | $421m | $547m | +32.8% | +29.9% | |
| Padcevpadcev_revenue | $508m | $591m | $667m | $720m | +55.2% | +7.9% | |
| Paxlovidpaxlovid_revenue | $218m | $186m | $21m | $449m | −63.3% | +2038.1% | |
| Prevnar familyprevnar_family_revenue | $1.71bn | $1.69bn | $1.34bn | $1.56bn | −10.2% | +17.0% | |
| Vyndaqel familyvyndaqel_family_revenue | $1.69bn | $1.6bn | $1.76bn | $1.77bn | +11.4% | +0.6% | |
| Abrysvoabrysvo_revenue | $481m | — | $208m | $303m | +8.6% | +45.7% | |
| Lorbrenalorbrena_revenue | $282m | — | $354m | $387m | +44.4% | +9.3% | |
| Xtandixtandi_revenue | $592m | — | $534m | $541m | −6.4% | +1.3% | |
| Oncology biosimilarsoncology_biosimilars_revenue | $369m | — | — | — | +76.6% | — |
Margins
4 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Cost of Sales Percent of Revenuescost_of_sales_pct_revenue | 30.0% | 24.6% | 27.2% | 24.3% | −2.8% | −10.7% | |
| Adjusted Cost of Sales Percent of Revenuescost_of_sales_pct_revenue_non_gaap | 28.9% | 23.6% | 24.3% | 23.2% | −2.9% | −4.5% | |
| Effective Tax Rate on Adjusted Incomeeffective_tax_rate_non_gaap | 23.3% | 16.9% | 14.1% | 14.0% | +77.2% | −0.7% | |
| Effective Tax Rate on Reported Incomeeffective_tax_rate | 0.1% | 14.6% | 62.4% | 3.9% | +160.0% | −93.8% |
Guided vs delivered
What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.
Data from company filings. Not investment advice.